Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | TTR | P02766 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31233320 | 1.00 | CYP19A1 (0.64) | CYP19A1PTPN1MAPTMEN1KMT2A | |
| SCHEMBL30384586 | 0.90 | PTPN1 (0.74) | CYP19A1PTPN1MAPTMEN1KMT2A | |
| SCHEMBL4216620 | 0.90 | PTPN1 (0.74) | CYP19A1PTPN1MAPTMEN1KMT2A | |
| SCHEMBL30383163 | 0.85 | MEN1 (0.65) | MAPTMEN1KMT2AKCNA3NPSR1 | |
| SCHEMBL3889916 | 0.85 | MEN1 (0.65) | MAPTMEN1KMT2AKCNA3NPSR1 | |
| SCHEMBL25206745 | 0.85 | MEN1 (0.65) | MAPTMEN1KMT2AKCNA3NPSR1 | |
| SCHEMBL1938672 | 0.82 | MEN1 (0.83) | MAPTMEN1KMT2AKCNA3NPSR1 | |
| SCHEMBL1938668 | 0.82 | MEN1 (0.83) | MAPTMEN1KMT2AKCNA3NPSR1 | |
| SCHEMBL25279943 | 0.80 | MGAM (0.63) | CYP19A1PTPN1MAPTMEN1KMT2A | |
| SCHEMBL25234217 | 0.80 | MGAM (0.63) | CYP19A1PTPN1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011513308-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2249641-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | Flaxan GmbH & Co. KG (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009108379-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | FLAXAN GMBH & CO. KG (US) | 2009-09-03 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-2249641-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | Flaxan GmbH & Co. KG (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009126320-A1 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS | BETAL, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009108379-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | FLAXAN GMBH & CO. KG (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | CYP19A1 270/4885PTPN1 1308/4885MAPT 3297/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | CYP19A1 320/4885PTPN1 1520/4885MAPT 3512/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | CYP19A1 320/4885PTPN1 1520/4885MAPT 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.